What Peptides Actually Are

A peptide is a short chain of amino acids joined by peptide bonds. Chains of roughly 2 to 50 residues are called peptides; longer than that and convention starts calling them proteins. There is no sharp biological boundary at 50. It is a naming habit, not a property of the molecule.

That definition is worth sitting with, because it means "peptide" tells you almost nothing about what a substance does. Insulin is a peptide. So is the venom component that made the first GLP-1 drugs possible. So is a research compound with fifteen residues and no human trials. Grouping them together is like grouping every wooden object as "furniture".

The vocabulary that actually matters#

Four terms do most of the work on this site.

Residue is one amino acid inside the chain. A pentadecapeptide has fifteen of them.

Sequence is the order of those residues, usually written in three-letter or one-letter code. Sequence determines shape, and shape determines what receptor the molecule can bind. Change one residue and you can get a different drug, or nothing at all.

Analogue means a molecule deliberately modified from a natural one. Semaglutide is a GLP-1 analogue: the backbone is recognisably the human hormone, with substitutions and a fatty acid chain added so it survives in the bloodstream for days instead of minutes.

Half-life is how long the substance persists before half of it is cleared. Native GLP-1 has a half-life of about two minutes. Semaglutide's is about a week. Almost all of the engineering effort in peptide drug design goes into that gap.

Why most peptides cannot be swallowed#

The gut is designed to destroy peptides. It is full of proteases whose entire job is breaking dietary protein into absorbable fragments, and a peptide drug looks exactly like food to them. Whatever survives then has to cross the intestinal wall, which small charged molecules do badly.

The result is that injectable administration is the default, not a marketing choice. Oral versions exist but they are hard-won. Oral semaglutide needs an absorption enhancer co-formulated with it and still delivers roughly one percent of the dose into circulation. That is considered a success.

This matters when you read product marketing. Oral and topical formulations of peptides are common in supplement channels, and for most sequences there is no plausible mechanism by which a meaningful quantity reaches the bloodstream intact.

The approved and the unapproved#

A large number of peptide drugs are approved, well-characterised, and unremarkable. Insulin has been in clinical use since 1922. Desmopressin, octreotide, leuprolide, teriparatide and the GLP-1 receptor agonists are all peptides. They went through trials, they have known adverse event profiles, and they are prescribed.

Most of what circulates in online peptide communities has not. Compounds like BPC-157 sit in a different category: promising preclinical data, essentially no controlled human evidence, no approval anywhere, and no supply chain accountable to a regulator. See BPC-157: What the Evidence Actually Shows for a worked example of how thin that evidence base can be while still generating confident claims.

Where to go next#

If you are trying to evaluate a specific compound, the skill you need is not chemistry. It is study appraisal, because the gap between "showed an effect in rats" and "works in humans" is where nearly every peptide claim falls apart. That is covered in How to Read a Peptide Study Without Being Fooled.

If you already have a vial and want to know whether it is what it claims to be, start with Third-Party Testing and What a COA Proves, then Storing and Handling Peptides Correctly.